Drug Search Results
More Filters [+]

Ombrabulin

Alternative Names: ombrabulin, ave-8062, ave8062, ave 8062
Latest Update: 2015-12-21
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Tubulin Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ombrabulin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Sarcoma

Phase 2: Non-Small-Cell Lung Cancer|Ovarian Cancer

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TCD11379

P1

Completed

Oncology Solid Tumor Unspecified

2014-10-01

OPSALIN

P2

Completed

Ovarian Cancer

2014-07-01

TCD11270

P1

Completed

Oncology Solid Tumor Unspecified

2013-10-01

2007-003592-39

P3

Completed

Sarcoma

2013-04-17

Recent News Events

Date

Type

Title